However, the picture above with so many happy faces, shows clearly that we are stronger than COVID-19 and that nothing can annihilate our passion, commitment, and devotion to the field of autoimmunity.
The EEMEAI Autoimmune Diagnostics (AID) Marketing Meeting on 26th - 27th May was conceived to share with our EEMEAI partners the vision, the strategy, and the ambitions we yearn to have.
The first day we started with an overview of the significant milestones we reached in 2020 and in the first part of 2021 from a reagent, software, and instrument perspective. We additionally shared our tactical 5 years plan to shed light on our main strategies in the autoimmunity field.
We reviewed, in details, the recent launch of new reagents on our BIO-FLASH platform, moving from Intrinsic Factor (IF) -a crucial biomarker for the identification of autoimmune gastritis- to Rheumatoid Factors – pivotal in Rheumatoid Arthritis.
We spent time with an in-depth analysis on the importance of our newly launched “circulating calprotectin” assay on Chemiluminescence platform regarding autoinflammatory disorders and COVID-19 poor prognosis. Such a revolutionary test, which represents a tremendous tool to identify autoinflammatory disorders, is the right candidate to become our top selling reagent within the next 5 to 10 years.
We devoted the rest of the morning session to the upcoming Aptiva platform which will lead us to the forefront of autoimmune diagnostics. We started with a comprehensive overview on the reagent pipeline and future developments; continuing then with newly generated clinical data gathered at customer sites from celiac to connective tissue disease.
Last session moved to the practical part of the Aptiva instrument, we played a live roadshow where Andrea De Cristofaro and Janarthan Panchakumar showed a video of an ongoing clinical evaluation in Pordenone – Italy, while performing a real-life experience on the Aptiva daily routine. Finally, an interactive session got started by navigating through the kiosk platform to highlight the value and the power of the particle based multi analyte technology (PMAT) and the user-friendly software with a complete overview of the different sections.
We wrapped up our sessions on May 27th with 3 experiences, the first was delivered by Jason Rogers, Scientific Affairs Manager at ILEX South Africa, who took us through the amazing journey of the Lancet laboratories’ success story. We were able to succeed against our main competitors Phadia and Euroimmun installing 3 Quanta Lyser 3000, 2 NOVA View and 3 BIO-FLASH.
The second experience comes from Yvonne Sundstrom, Product Manager at Mediq Sweden, who took us through the successful installation of the first integrated lab in the country, thus creating the first real Werfen autoimmunity reference centre in Sweden.
Our third and final experience was focused on BIO-FLASH strategy in Saudi Arabia. Our colleague Mustafa Abu Hamdeh, business unit manager immunology at Abdulla Fouad for Medical Supplies and Services Company, illustrated the steps implemented to secure AID business in the Kingdom. In five years, we were able to install over 25 BIO-FLASH units.
Finally, our colleague Farid Abderrahmani, Werfen Business Unit Manager at BH LAB Algeria, in the joint session of Quality Workshop, presented a detailed and very comprehensive overview of our IT middleware solution QUANTA Link.
Thank you all for being so dedicated and interactive during the entire sessions!
Stay safe!
Keep the flame of autoimmunity high!
Autoimmunity Marketing Team



